CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 87 enrolled
Drug / intervention
MRI guided transurethral HIFU ablation of prostatic tissuedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03350529
NCT03350529N/ACompleted
CompareCT.gov

Feasibility and Safety of Transurethral HIFU in Various Prostate Diseases; Particularly Prostate Cancer

Turku University Hospital·interventional·Posted Nov 22, 2017·Updated Nov 25, 2024

In Brief

A clinical study evaluating MRI guided transurethral HIFU ablation of prostatic tissue for Localised Prostate Cancer and 3 related conditions. Completed, enrolled 87 participants across 1 site.

Detailed Summary

This study assesses feasibility and safety, the primary outcomes, of MRI guided transurethral high intensity focused ultrasound (HIFU) ablation for prostate diseases (PD). We will enrol 10 patients to each group with criteria as follows: localised prostate cancer (PC); locally advanced PC; locally recurrent PC after external beam radiation therapy (EBRT); benign prostatic hyperplasia (BPH). Secondary outcomes are both oncologic and functional outcomes and imaging based follow up after HIFU therapy will be also assessed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLocalised Prostate Cancer, Locally Advanced Prostate Cancer, Locally Recurrent Prostate Cancer, Benign Prostatic Hyperplasia
CountriesFinland
CollaboratorsUniversity of Turku

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedNov 22, 2017
Enrollment StartJul 24, 2017
Primary CompletionMay 31, 2024
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 8.6 years ago

Interventions

MRI guided transurethral HIFU ablation of prostatic tissuedevice

The technology is developed to ablate targeted benign and malignant prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.